Publications by authors named "Jacqueline C Barrientos"

41Publications

Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing Era.

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:487-498. Epub 2019 May 17.

2 Northwell Health Cancer Institute, Zucker School of Medicine at Hofstra/Northwell, Feinstein Institute for Medical Research, CLL Research and Treatment Program, New Hyde Park, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_238735DOI Listing
January 2019

Chylothorax in Patients with Chronic Lymphocytic Leukemia: A Case Series.

J Hematol 2018 Jan;7(1):14-18

Department of Medicine Hofstra Northwell School of Medicine, New Hyde Park, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14740/jh339wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173329PMC
January 2018

Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.

Leuk Lymphoma 2019 04 2;60(4):1000-1005. Epub 2018 Oct 2.

f Department of Medicine , University of California San Diego, Moores Cancer Center , San Diego , CA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2018.1512710DOI Listing
April 2019

Can umbralisib bring PI3Kδ out of the shadows?

Lancet Oncol 2018 04 20;19(4):432-434. Epub 2018 Feb 20.

Feinstein Institute for Medical Research, Zucker School of Medicine, New Hyde Park, NY 11021, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30154-2DOI Listing
April 2018

Ventricular arrhythmias and sudden death in patients taking ibrutinib.

Blood 2017 05 21;129(18):2581-2584. Epub 2017 Feb 21.

Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-10-742437DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219062PMC
May 2017

Sequencing of chronic lymphocytic leukemia therapies.

Hematology Am Soc Hematol Educ Program 2016 Dec;2016(1):128-136

CLL Research and Treatment Program, Department of Internal Medicine, Hofstra Northwell School of Medicine, New Hyde Park, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2016.1.128DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142523PMC
December 2016

Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.

Future Oncol 2016 Sep 21;12(18):2077-94. Epub 2016 Jun 21.

CLL Research & Treatment Program, Division of Hematology/Oncology, Department of Medicine, Hofstra Northwell School of Medicine, Hofstra University, 410 Lakeville Road, Suite 212, Lake Success, NY 11042, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2016-0003DOI Listing
September 2016

Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential.

Onco Targets Ther 2016 18;9:2945-53. Epub 2016 May 18.

CLL Research and Treatment Program, Division of Hematology/Oncology, Department of Medicine, Hofstra Northwell School of Medicine, Hofstra University, Lake Success, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S102573DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876096PMC
June 2016

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

N Engl J Med 2016 Jan 7;374(4):323-32. Epub 2015 Dec 7.

From the Division of Hematology, Department of Internal Medicine, Ohio State University (J.C. Byrd, J.A.J., F.T.A., J.W., A.J.J.), and the Department of Veterinary Biosciences, College of Veterinary Medicine (B.H.) - both in Columbus; UC Irvine Health Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange (S.O.); University of Oxford, Oxford (A.S.), NHS Foundation Trust, King's College Hospital, London (S.D.), and the Department of Haematology, St. James's University Hospital, Leeds (P.H.) - all in the United Kingdom; Northwest Medical Specialties, Tacoma (J.C.), and the Swedish Cancer Institute, Seattle (J.M.P.) - both in Washington; the Department of Leukemia, Division of Cancer Medicine, University of Texas, and M.D. Anderson Cancer Center - both in Houston (W.G.W.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); Huntsman Cancer Institute, University of Utah, Salt Lake City (D.M.S.); Università Vita-Salute San Raffaele and Istituto Scientifico San Raffaele, Milan (P.G.); Hofstra North Shore-LIJ School of Medicine, Chronic Lymphocytic Leukemia Research and Treatment Center, Lake Success (J.C. Barrientos), and the Department of Pathology and Cell Biology, Columbia University Medical Center (T.G.D.), and New York-Presbyterian/Weill Cornell Medical Center, New York (R.R.F.) - all in New York; and Acerta Pharma, Oss, the Netherlands (D.J., J.H., X.W., A.K., B.J.L., T.C., M.F., J.M., A.H., W.R., R.I.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1509981DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862586PMC
January 2016

Management of Chronic Lymphocytic Leukemia in the Elderly.

Cancer Control 2015 Oct;22(4 Suppl):17-23

Hofstra North Shore-LIJ School of Medicine, CLL Research and Treatment Program, New Hyde Park, NY 11042, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763599PMC
http://dx.doi.org/10.1177/107327481502204s04DOI Listing
October 2015

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

N Engl J Med 2014 Jun 28;370(24):2286-94. Epub 2014 May 28.

From the Division of Hematology, Department of Internal Medicine (J.A.W., T.-M.L., A.S.R., S.M.J., K.A.B., A.L., A.J.J., J.C. Byrd), the Department of Biomedical Informatics (H.G.O., A.S.Y.), and the Department of Pathology (G.L.), Ohio State University, Columbus; the Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medical College, New York (R.R.F.); the Division of Molecular Genetics, German Cancer Research Center, Heidelberg (M.Z., P.L.), and the Department of Internal Medicine III, University of Ulm, Ulm (S.S.) - both in Germany; Pharmacyclics, Sunnyvale, CA (L.X., D.H.-H.L., S.M.S., D.F.J., J.J.B., B.Y.C.); the Duke Cancer Institute, Duke University, Durham, NC (S.S.D., J.Z.); the Division of Hematology-Oncology, Department of Medicine, Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY (J.C. Barrientos); and Janssen Research and Development, Beerse, Belgium (M.V.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1400029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144824PMC
June 2014

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.

J Clin Oncol 2014 Jul 27;32(19):2067-73. Epub 2014 May 27.

Danelle F. James, Januario E. Castro, Andrew Greaves, Laura Z. Rassenti, Thomas J. Kipps, Moores Cancer Center, University of California San Diego, La Jolla, CA; Lillian Werner, Jennifer R. Brown, Donna Neuberg, Dana-Farber Cancer Institute, Boston, MA; William G. Wierda, MD Anderson Cancer Center, The University of Texas, Houston, TX; Jacqueline C. Barrientos, Kanti R. Rai, North Shore-Long Island Jewish Health System, New Hyde Park, NY; Amy J. Johnson, The Ohio State University, Columbus, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.5890DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067945PMC
July 2014

Movement toward optimization of CLL therapy.

N Engl J Med 2014 Mar;370(12):1160-2

From the Hofstra North Shore-LIJ School of Medicine and the North Shore-LIJ Cancer Institute - both in Lake Success, NY; and the Feinstein Institute for Medical Research, Manhasset, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1400599DOI Listing
March 2014

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

N Engl J Med 2014 Mar 22;370(11):997-1007. Epub 2014 Jan 22.

Weill Cornell Medical College (R.R.F.), Memorial Sloan-Kettering Cancer Center (A.D.Z.), the Department of Medicine, and Columbia University Medical Center (N.L.) - all in New York; U.S. Oncology Research, Springfield, OR (J.P.S.); Stanford University School of Medicine, Stanford (S.E.C.), and Gilead Sciences, Foster City (M.A., D.M.J., L.L.M., D.L., T.M.J., R.D.D.) - both in California; Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC (B.D.C.); Fred Hutchinson Cancer Research Center, University of Washington, Seattle (J.M.P.); St. James's University Hospital, Leeds (P.H.), and Royal Liverpool University Hospital, Liverpool (A.R.P.) - both in the United Kingdom; Hofstra North Shore-LIJ School of Medicine, New Hyde Park, New York (J.C.B.); University of California San Diego, Moores Cancer Center, La Jolla (T.J.K.); Sarah Cannon Research Institute, Nashville (I.F.); Universita Vita-Salute San Raffaele, Instituto Scientifico San Raffaele, Milan (P.G.); David Geffen School of Medicine, University of California Los Angeles, Los Angeles (H.E.); Florida Cancer Specialists, Englewood (T.E.); Centre Hospitalier Lyon-Sud, Pierre-Bénite, France (B.C.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (S.M.); University of Ulm, Ulm (S.S.), and University of Cologne, Cologne (P.C., M.H.) - both in Germany; and University of Texas M.D. Anderson Cancer Center, Houston (S.M.O.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1315226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161365PMC
March 2014